If you live with HIV and have wondered whether swapping daily pills for shots holds up outside a clinical trial, there's new evidence. On October 21, 2026, ViiV Healthcare, the company that makes the long-acting HIV treatment Cabenuva, announced five years of US real-world data from the OPERA cohort, presented at IDWeek 2026 in Washington, DC.

The short version: Among nearly 7,000 people who switched from daily pills to Cabenuva injections, 94% had an undetectable viral load at their last test, 81% stayed suppressed at every single visit, and only 1% had confirmed treatment failure. That matters for health, and it matters for dating, because staying undetectable is what makes U=U (undetectable = untransmittable) possible.

What is Cabenuva?

Cabenuva is a complete HIV treatment regimen made of two long-acting drugs, cabotegravir and rilpivirine, given as injections into the buttock muscles by a health care provider. Depending on the schedule, people get their shots either once a month or once every two months instead of taking a daily pill. It has been on the US market since 2021.

According to the FDA-approved prescribing information, it's meant for people who are already undetectable (under 50 copies/mL) on a stable regimen, with no history of treatment failure and no known or suspected resistance to either drug. In other words, it's a switch option for people who are doing well, not a starting treatment for someone just diagnosed.

What the five-year OPERA data found

OPERA is a large US observational cohort that follows people in routine HIV care. According to ViiV Healthcare's October 21, 2026 announcement:

• The group was large and diverse. The analysis included 6,955 adults who were already virally suppressed and switched from daily oral treatment to Cabenuva between January 2021 and December 2025, followed through February 2026. 43% were Black, 32% were Hispanic/Latine, 23% were 50 or older and 57% lived in the Southern US.
• Most people stayed on it. Among 6,362 people who completed their first two injections, 77% were still in care and on Cabenuva, with a median treatment time of 18 months.
• Viral suppression held up. Among 6,058 people with follow-up viral load results, 94% had a last viral load under 50 copies/mL, and 81% stayed under that level at every visit.
• Treatment failure was rare. 1% (68 people) had confirmed virologic failure.
• Why people stopped. Among 213 confirmed discontinuations, the most common reasons were adherence issues (28%), loss to care (24%) and preferring another regimen (15%).

Lead author Dr. Ricky K. Hsu said discontinuations "were low and not commonly attributed to a lack of therapeutic efficacy or injection site pain."

What independent coverage added

CIDRAP's report on the study noted that 95% of patients got their shots on time or had only one late injection. It also reported that only about 5% of people with HIV take Cabenuva, according to Dr. Hsu. An HIV specialist who wasn't involved in the study, physician assistant George Froehle, told CIDRAP that for some patients a daily pill is an unwelcome reminder of their diagnosis, and that switching lets people "think less about their HIV infection, and they still remain undetectable."

Keep it in perspective

This is real-world observational data, not a randomized trial, and it was announced by the drug's manufacturer and presented at a conference rather than published as a full peer-reviewed paper. The median time on treatment was 18 months, so the "five years" describes how long the cohort has been collecting data, not how long each person was on the shots. Still, results from nearly 7,000 people in everyday care, including groups often underrepresented in trials, are meaningful.

What this means for dating

Here's what matters most for our community: U=U doesn't care whether you get there with pills or shots. The CDC says a person with HIV who takes HIV medicine as prescribed and gets and stays virally suppressed or undetectable will not transmit HIV to their sex partners. You can read more in our guide to what U=U means for dating and relationships.

What a long-acting option can change is the day-to-day experience:

• Less daily reminder. For some people, not seeing a pill bottle every morning takes real weight off.
• Disclosure is still your call. Your treatment method doesn't change how or when you share your status. If you're working out that conversation, our guide on how to tell someone you have HIV can help.
• Appointments become the new adherence. With shots, staying protected means keeping your injection visits. If you miss a visit or stop, the medicine fades slowly, so talk to your provider right away about a backup plan.
• Mixed-status couples have more tools than ever. An undetectable partner, PrEP for an HIV-negative partner and condoms can all work together. See building healthy relationships with different HIV statuses and how condoms, antivirals and PrEP layer together.
• Other STIs still need attention. The CDC notes that being undetectable does not protect against other sexually transmitted infections, so regular testing still matters.

Is switching right for you?

Cabenuva isn't for everyone. Ask your HIV provider about:

• Eligibility. You generally need to be undetectable on a stable regimen with no known resistance to cabotegravir or rilpivirine. Froehle told CIDRAP that about 10% of people with HIV have virus resistant to rilpivirine, and that Cabenuva isn't appropriate for people living with both HIV and hepatitis B.
• Side effects. The most common side effects in the prescribing information are injection site reactions, fever, fatigue, headache, muscle or bone pain, nausea, sleep problems, dizziness and rash. Froehle told CIDRAP the shots can cause muscle soreness for a couple of days, but most people tolerate them well.
• Your schedule. Monthly or every-two-month clinic visits need to fit your life, work and travel.
• Stopping safely. The drugs can stay in your body for 12 months or longer after your last shot, so if you stop, you'll need to start a fully suppressive regimen on time to avoid resistance.

FAQ

Does Cabenuva work as well as daily pills for U=U?

What matters for U=U is staying undetectable, not the form of the medicine. In this real-world cohort, 94% of people with follow-up results were undetectable at their last test. Regular viral load testing confirms it, whether you take pills or shots.

Is Cabenuva a cure for HIV?

No. Like daily pills, it keeps HIV suppressed while you stay on it. It doesn't remove HIV from the body.

Is this the same as the PrEP shot?

No. Cabenuva is treatment for people living with HIV. HIV-negative people can use separate long-acting PrEP shots to prevent HIV, which is a conversation for their own provider.

Do I have to tell a date which HIV treatment I'm on?

No. What you share about your treatment is up to you. Many people find that explaining U=U is more helpful to a partner than naming a specific medication.

The bottom line

Five years of US real-world data suggest long-acting injectable treatment keeps the vast majority of people undetectable, with rare treatment failure. For people dating with HIV, that's one more path to the same powerful outcome: a healthy life and no risk of passing HIV to a partner through sex. If you're ready to meet people who already get it, explore HIV dating on MeetPositives.

Sources

• ViiV Healthcare, "Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare's Cabenuva," October 21, 2026 (Hsu RK, et al., IDWeek 2026).
• CIDRAP, "Long-acting injected combo drug keeps HIV in check, real-world study finds," October 2026.
• CDC, "HIV Treatment as Prevention."
• Cabenuva US Prescribing Information (revised November 2025).

This article is for general information only and is not medical advice. Talk with your health care provider before making any changes to your HIV treatment.